GL Pharm Tech Corp. Logo

GL Pharm Tech Corp.

Develops incrementally modified drugs using advanced drug delivery technologies.

204840 | KO

Overview

Corporate Details

ISIN(s):
KR7204840003
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 달래내로 46 성남글로벌융합센터 210호, 성남시

Description

GL Pharm Tech Corp. is a pharmaceutical company specializing in the development of incrementally modified drugs (IMDs). The company focuses on creating improved versions of existing pharmaceutical products by utilizing advanced drug formulation and delivery technologies. Its core mission is to enhance the therapeutic value and safety of marketed drugs, with a specific emphasis on reducing side effects and improving patient convenience. GL Pharm Tech is actively engaged in research and development, managing a pipeline of drug candidates and conducting clinical trials to support the commercialization of its enhanced pharmaceutical products.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-12-01 00:00
주식등의대량보유상황보고서(일반)
Korean 84.1 KB
2023-11-30 00:00
최대주주변경을수반하는주식양수도계약체결
Korean 23.5 KB
2023-11-30 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 30.8 KB
2023-11-30 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 30.2 KB
2023-11-10 00:00
분기보고서 (2023.09)
Korean 1.1 MB
2023-11-10 00:00
[기재정정]반기보고서 (2023.06)
Korean 1.0 MB
2023-10-17 00:00
풍문또는보도에대한해명(미확정)
Korean 5.6 KB
2023-10-10 00:00
주식등의대량보유상황보고서(약식)
Korean 60.8 KB
2023-09-14 00:00
투자판단관련주요경영사항(최대주주 변경을 수반하는 주식매매계약을 위한 양해각서(MOU) 체결)
Korean 8.6 KB
2023-09-14 00:00
주요사항보고서(유상증자결정)
Korean 28.5 KB
2023-08-11 00:00
반기보고서 (2023.06)
Korean 1.0 MB
2023-07-28 00:00
[기재정정]사업보고서 (2022.12)
Korean 1.5 MB
2023-05-09 00:00
분기보고서 (2023.03)
Korean 1.1 MB
2023-03-27 00:00
정기주주총회결과
Korean 21.8 KB
2023-03-27 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 8.8 KB

Automate Your Workflow. Get a real-time feed of all GL Pharm Tech Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GL Pharm Tech Corp.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GL Pharm Tech Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.